Nanoparticle Platforms in Oncology and Chronic Disease Management: Emerging Paradigms in Targeted Therapeutics

Praveen J R[1]*, Dr. Prafulla Prakash Adkar Patil[2]
1 Research Scholar, Sunrise University, Alwar, Rajasthan, India
praveenjavalisgk1997@gmail.com
2 Professor, Department of Pharmaceutical Sciences, Sunrise University, Alwar, Rajasthan, India

Abstract: Pharmaceutical scientists have developed nanoparticle based drug delivery systems as revolutionary advances for pharmaceutical science and specifically for the treatment of cancer and chronic illnesses. The increasing number of people suffering from conditions—such as cancer-related disorders; diabetes; cardiovascular diseases; and neurodegenerative diseases—around the world has created an urgent need for therapeutic strategies that are precise, efficient, and beneficial to patients. Limitations of traditional drug delivery methods frequently result in poor bioavailability of the drug used, inability to deliver to a specific target, toxicities to adjacent body systems, and poor patient compliance. As a result of these limitations of traditional drug delivery techniques, nanoparticle platforms (e.g., liposomes, dendrimers, and metallic nanoparticles) can be utilized to overcome traditional limitations of drug delivery by facilitating targeted drug delivery; facilitating controlled release of therapeutic drugs; and improving the pharmacokinetic properties of the drug.

This research paper uses a qualitative analysis of previously published works and research done internationally regarding the industry of pharmaceuticals to infer the characteristics of the leading nanoparticle-based platform types, the types of mechanisms they use to target delivery, and their uses for cancer treatment and the management or prevention of chronic diseases. It also identifies various issues associated with toxicology, regulations, developing processes, and clinical application for these types of products. The results yield strong evidence of the advantages to using nanoparticle systems as a means of increasing efficacy of treatment, limiting adverse treatment effects, and providing tools for providing precision medicine. However, due to safety issues, the complexity of their manufacturing processes, and lack of clarity in regulatory guidelines, the widespread adoption of nanoparticle systems has not yet occurred.

Finally, the authors conclude from their analyses that the use of nanoparticles for the purpose of targeted therapeutic delivery has tremendous potential to create change in the way we currently think about targeted therapeutics and provide solutions not previously imaginable. In order for nanoparticle systems to be adopted into clinical practice, regulatory agencies will need to create supportive regulatory frameworks that enhance the research conducted on the long-term safety of the products; there will need to be further investigation done on scalability of manufacturing of nanoparticle systems; and there will need to be significant research conducted that will support their applications of use in hospital and clinical settings.

Keywords: Nanoparticle drug delivery, targeted therapeutics, oncology treatment, chronic disease management, nanomedicine

1. INTRODUCTION

Drug delivery systems based on nanoparticles represent a changing technology in the development of drugs for disease treatment, specifically for complex diseases like the treatment of cancer and chronic disease management. Nanoparticles are used as nanoscaled carriers, generally between 1 and 100 nanometers, to deliver therapeutic agents more accurately and efficiently. Because nanoparticles have unique physical and chemical characteristics including large surface-area-to-volume ratio, adjustable surface chemistry, and the capacity to encapsulate many different types of drug molecules, they have allowed for significant advancements in targeted therapies (Peer et al., 2007; Bobo et al., 2016). In the field of oncology, nanoparticle systems have been used extensively to deliver chemotherapy directly to a patient's tumor site in order to decrease the systemic toxicity experienced from chemotherapy and to improve patient outcomes from chemotherapy. In addition, nanoparticles provide opportunities for extended release of drugs in chronic diseases such as diabetes and cardiovascular disease which results in improving patient adherence to therapy and represents a change from the traditional methods of treating these types of diseases (Ventola, 2017).

The increasing number of cancer cases and other long-term illnesses throughout the world from 2000 to 2020 has created a strong demand for new means of delivering drugs. The World Health Organization (WHO) reports that cancer is one of the top ten reasons people die each year (nearly 10 million) and chronic diseases, such as diabetes and heart disease, also create excessive costs and morbidity (World Health Organization, 2023). Neurological types of disease, which are caused mostly by aging populations, such as Alzheimer's and Parkinson's disease, will also increase and create a new challenge to therapeutic interventions. Long-term treatments on these diseases will frequently be limited in terms of developing drug resistance, poor adherence by patients and/or ineffective therapeutic delivery. Therefore, the need for advanced drug delivery systems that provide a targeted, efficient and long-lasting therapeutic effect is urgent.

Conventional drug delivery systems have a number of critical limitations. These include low bioavailability due to rapid degradation of the drug, non-specific distribution resulting in damage to healthy tissues, and systemic toxicity resulting in unwanted side effects. In addition, traditional drug formulations often require repeated dosing, impacting a patient's compliance and treating them effectively (Allen & Cullis, 2013). In oncology, it is particularly evident that

a very high dose of chemotherapeutic agent is typically needed to create a therapeutic effect; their use often causes severe toxicity. In chronic disease management, drug levels cannot be maintained in the body consistently; therefore, there are fluctuating therapeutic responses. The limitations of conventional drug delivery systems indicate the need for new technologies that can overcome these barriers.

Many different types of nanoparticle platforms (i.e., liposomes, dendrimers and metallic nanoparticles) have been developed to help overcome the challenges associated with traditional drug delivery systems. Liposomes, which are made up phospholipid bilayers, are able to carry both water-soluble (hydrophilic) and lipid-soluble (hydrophobic) drugs in their core and improve the stability of both drug types, thus increasing their efficiency in terms of delivery (i.e., decreased dosages). In contrast to liposomes, dendrimers have a highly branched structure, allowing them to carry many different types of 'functional groups' to enable the targeted delivery of specific drugs to specific diseased tissues. With respect to drug delivery systems using metallic nanoparticles, both gold and silver nanoparticles provide unique optical and thermal properties suitable for use in diagnostic imaging and in targeted therapeutic applications such as photothermal therapy (Torchilin, 2014; Farokhzad & Langer, 2009). Collectively, these nanoparticle platforms provide two major benefits: the ability to increase drug(s) bioavailability and the ability to permit controlled/sustained drug release to decrease the frequency of dosing (therefore reducing possible side effects).

Nanoparticle therapies have become increasingly prevalent due to factors such as rapid progress in nanotechnology, an increased demand for personalised medical treatment, and a shift in pharmaceutical research trends. The marriage of biotechnology with materials science through the use of nanotechnology has led to advances in drug delivery systems that can be tailored to the specific needs of individual patients. As such, the rise of personalised medicine—which aims to tailor treatment based on genetics, environment, and lifestyle—has further increased the demand for nanoparticles for targeted therapeutic use. Increasing investment in nanomedicine research and government support for regulatory initiatives has further fueled interest in this rapidly growing field (Shi et al., 2017).

Nanoparticles are garnering increased interest across a wide range of therapeutic applications. For example, nanoparticle-mediated cancer chemotherapy allows for enhanced targeting of tumor cells while reducing toxicity to normal (non-tumor) cells. Likewise, nanoparticle

carriers used for insulin delivery are being investigated with the goal of improving blood sugar levels (glycemic control) in diabetic patients. Also, in gene therapy and immunotherapy, they are used to precisely deliver nucleic acids or immune-modulating agents. Finally, the success of lipid nanoparticles in delivering mRNA vaccines during the COVID-19 pandemic has validated their role within the realm of contemporary medicine (Pardi et al., 2018).

In spite of these rapid developments and improvements in nanoparticle systems within a short time period, there are many difficulties that hinder the general use of drug delivery systems based on nanoparticle technology in clinical settings. Concern regarding the long-term safety of using nanoparticles, their potential for toxicity, as well as issues related to biocompatibility (e.g., does the substance harm healthy cells?), are all still significant barriers to widespread use. Also, problems with scalability (producing enough quantity of product) and high costs associated with producing large quantities of nanoparticles are all challenges to production and commercialization. Also, there are no clear regulations governing the testing of these types of therapeutic agents (e.g., there are no "standard" methods for testing nanoparticles). Furthermore, more research is needed to determine how nanoparticles can be tailored specifically for various diseases prior to gaining approval from the appropriate authorities.

In this regard, this article aims to evaluate the role and potential effectiveness of nanoparticles as a platform for use in cancer therapy and chronic disease management. This paper will provide a critical evaluation of the application of nanoparticles for these target diseases, outline the primary obstacles to their development, and outline potential future work necessary to advance the development of targeted therapies.

The qualitative study analysed through a qualitative approach through a thorough analysis of scientific, peer-reviewed open access journals, international health reports and pharmaceutical research publications. Data were collected and systematically analysed with thematic and comparative techniques to produce a better understanding of key trends, uses and challenges associated with nanoparticle platforms and their implementation in improving therapeutic outcomes.

2. NANOPARTICLE PLATFORMS AND MECHANISMS IN TARGETED DRUG DELIVERY

Platforms that are nanoparticle-based are designed to be carrier systems on the nanoscale that provide improved delivery of therapeutic agents with greater efficacy and safety. The major

classifications used in pharmaceutical science are lipid-based, polymeric, dendritic and metallic nanocarrier systems. Nanoparticle systems are classified by their composition and functional characteristics which distinguishes their .physicochemical properties including size, surface charge, drug loading capacity and release kinetics that are relevant for their clinical application. The increased use of nanoparticles in enhancing targeted drug delivery, improving pharmacokinetics and providing innovative means for treating patients with both cancer and chronic disease has been demonstrated through multiple studies (Patra et al., 2018).

Of all the main nano-based particle systems; liposomes are perhaps the best-studied and have been clinically approved as a drug delivery system. A liposome is a type of spherical vesicle with a lipid bilayer of phospholipids surrounding an aqueous core that can hold both water-soluble and fat-soluble (hydrophilic and hydrophobic) drugs. Due to their structural similarity to the biological membrane, they exhibit excellent biocompatibility and minimal immunogenicity. They also protect drugs from being degraded during transport while providing targeted delivery through surface modifications; therefore, liposomes are very useful for treating cancer with chemotherapy (Sercombe et al., 2015).

Dendrimers are also an essential category of nanomaterials that exhibit the branched 'tree-like' nature and functioning with numerous functional groups on the exterior of their structure. On their surface, dendrimers can be "tagged" with drugs, targeting ligands, and imaging agents. Due to their regular size and uniformity, they provide a precise method for delivering drugs and have enhanced cell uptake rates, especially for targeted treatments for cancer, neurological disorders (Kesharwani et al., 2014).

Ceramic nanoparticles, specifically gold nanoparticles, have been shown to possess interesting optical, electronic and thermal characteristics that make them highly sought after. These nanoparticles serve a dual purpose by being used as therapeutic agents and diagnostic tools; an example of which would be photothermal therapy where nanoparticles are used to create heat when exposed to light for the selective killing of cancerous cells. However, there is still much that needs to be done in order to fully understand the potential long-term toxicity and accumulation of these materials (Dykman & Khlebtsov, 2012).

A diverse drug delivery platform can be provided for the use of nanoparticles in drug delivery via either a polymeric base or a lipid base. Polymeric nanoparticles are prepared from degradable polymers and allow for the sustained and controlled release of therapeutic agents

when used for the management of chronic diseases. Lipid-based nanoparticles (e.g., solid lipid nanoparticles) will increase the solubility and stability of poorly water-soluble drugs, resulting in improved efficacy of those drugs (Mukherjee et al., 2009).

There are various mechanisms involved in the successful delivery of drug products via nanoparticles to their target sites. Ligand-receptor mediated targeting is one mechanism. Through the use of appropriate ligands that bind to specific receptors on the surface of target cells, nanoparticles can deliver therapeutics precisely at the specified anatomical locations. The EPR (Enhanced Permeability and Retention) effect is another mechanism. With the presence of leaky blood vessels and underdeveloped lymphatic channels, nanoparticles can accumulate in tumor tissues via the EPR effect. Additionally, because of their time-dependent release capabilities, nanoparticles can provide a sustained concentration of the therapeutic agent at the desired site of action, resulting in the ability to reduce the number of times the patient needs to receive the therapeutic agent during the course of his/her treatment regimen (Maeda et al., 2013).

Nanoparticle delivery systems greatly aid in bioavailability by improving the Solubility of drugs and protecting them from enzymatic degradation. In addition to this, these delivery systems reduce systemic toxicity by providing methods of delivering drugs to the diseased tissue and thus reducing exposure risk to healthy cells. The directed method of delivery leads to increased treatment efficacy and patient safety, especially in terms of cancer therapy. (Anselmo & Mitragotri, 2019)

Each of the various systems of nanoparticles has its use and respective advantages based on a comparative analysis of the various nanoparticle systems. For example, liposomes have high biocompatibility; dendrimers provide very precise targeting capabilities; metallic nanoparticles can be used as multifunctional therapeutic systems; and polymers will allow for extended or sustained release of drugs/device. The appropriate selection of a nanoparticle platform is dependent on the therapeutic objectives, the disease type, and the consideration for safety.

The design and functionalization of nanoparticles are critical components to providing a means to enable precision and personalized medicine. Customization of the size, surface chemistry, and/or targeting ligands of nanoparticles allows for nanoparticles to be tailored to fit the needs

of each patient, ultimately improving therapeutic impacts and further developing the future of targeted drug delivery (Anselmo & Mitragotri, 2019).

3. APPLICATIONS IN ONCOLOGY AND CHRONIC DISEASE MANAGEMENT

Nanoparticle platforms have assumed a critical role in oncology, enhancing the delivery of anti-cancer agents to tumor tissue, while minimizing the weaknesses of conventional chemotherapy. Many small-molecule drugs used for cancer treatment are rapidly eliminated from circulation and cause significant toxicity to healthy tissue due to their inability to discriminate between normal and malignant cells. Nanoparticle systems improve pharmacokinetics (the kinetics of drug distribution) by increasing the concentration of drugs at the site of a tumor and enhancing the targeting of tumor tissues. There are also numerous reports within the scientific literature indicating that lipid-based formulations are the most approved and widely used nano-pharmaceuticals for the treatment of cancer and thus have clinical significance in the development of new targeted therapies (Rodríguez et al., 2022).

One notable application of nanomedicine in cancer treatment is in the use of targeted chemotherapeutics via passive and active tumor accumulation mechanisms. Passive targeting relies mainly on the enhanced permeability and retention effect, while active targeting utilizes ligand-receptor interactions between tumor cells and angiogenic endothelial cells to enhance the delivery of therapeutics to the cancer site. Each method enhances the concentration of drug at the disease site and reduces systemic toxicity. These benefits of passive and active targeting are especially important, given that traditional chemotherapeutic agents generally exhibit poor pharmacokinetics and extensive biodistribution (i.e., are widely distributed throughout the body). Overall, nanoparticle carriers demonstrate improved pharmacodynamics of the payloads they carry; a greater degree of controlled release of the payload; and increased selectivity of the payload to the intracellular location of the cell, which is essential for the successful implementation of modern cancer nanomedicine (Danhier et al., 2010).

Various types of nanoparticles are extending the range of oncology by utilizing immunotherapy and gene therapy. For example, lipid-based nanoparticles have become the preferred non-viral delivery mechanism for small interfering (siRNA) molecules, messenger RNAs (mRNA), plasmid DNA, and gene editing materials. Lipids protect nucleic acids from degradation, create a more robust formulation than traditional methods allow, and enable some level of cellular delivery in amounts needed to achieve meaningful outcomes clinically. So,

instead of just transporting traditional cancer drugs, lipid-based nanoparticles are also being used to deliver RNA therapeutics, develop vaccines, and use gene-editing methods. Ultimately, such delivery systems are particularly important for treating tumors that utilize very specific or molecularly directed therapeutic agents (Cullis & Hope, 2017).

Nanoparticles are becoming more important in chronic disease management as chronic diseases often require long-term treatment and accurate dosing without being invasive to the patient. In diabetes, advances in nanotechnology have allowed for the development of glucose-sensitive glucose sensing and insulin delivery systems which reduce the frequency and invasiveness of insulin administration improving patient comfort and enhancing overall well-being. For pharmaceutical applications, nanoparticles have been studied in order to enhance the efficacy of treatment on many aspects of cardiovascular disease including atherosclerosis, myocardial infarction, thrombosis, and restenosis by providing improved targeted delivery and localized release of drug molecules as well as providing new options for theranostic imaging. Nanoparticles can improve the delivery, bioavailability, and pharmacodynamic effects of therapeutics for patients with neurodegenerative disorders as they can be manufactured to pass through or bypass the blood-brain barrier in order to achieve optimal drug delivery into the CNS where conventional therapies prove ineffective (DiSanto et al., 2015; Omidian et al., 2023; Wechsler et al., 2019).

The collective body of research shows that nanoparticles can enhance the effectiveness of a medicine, decrease its side effects, and encourage patients to adhere to treatment regimens by allowing for an extended duration of release overall and a spatially preferential route of administration with fewer doses over time. The newest advancements in drug formulations (nucleic-acid nanocarriers), controlled-release technology (smart drug-delivery systems), and stimuli-responsive formulations are demonstrating that nanoparticles are transitioning from a passive mode of delivery into a multi-functional mode of therapeutic systems assisting with the challenges associated with long-term management of diseases that cannot be effectively or safely managed using conventional methods (Rodríguez et al., 2022; Omidian et al., 2023).

4. CHALLENGES, REGULATORY CONCERNS, AND FUTURE PROSPECTS

Despite the vast promise that nanoparticle-based drug delivery systems possess, there are numerous significant hurdles preventing their clinical implementation on a widespread basis. Chief among these is biocompatibility and toxicity issues with long term exposure. Although

they were developed to enhance therapeutic targeting, nanoparticles' small size and high surface reactivity can produce unintended interactions with living systems which could produce an immunogenic reaction, induce oxidative stress, or accumulate in organs. Numerous studies have indicated that the toxicity of nanoparticles depends on multiple factors such as the composition of the nanoparticles, their size, and surface characteristics; therefore, toxicity evaluations are complicated and are strongly context dependent (Buzea et al., 2007).

Stability and degradation of nanoparticle systems are also a major issue because of the lack of physical or chemical stability of these formulations during storage, circulation, and drug delivery due to the effect of the surrounding environment on drug release profiles which reduces therapeutic efficacy and general dimensions and volume present problems in the production of these types of materials at scale; maintaining the structural integrity of these types of materials in a physiological environment is a significant limitation to these types of materials (Sercombe et al., 2015).

Another considerable barrier related to cost and complexity in manufacturing such types of products due to the current technologies needed to produce nanoparticles require special tools, an extreme level of control over physicochemical properties, high levels of quality control to ensure product quality, all of which increase production costs and limit availability particularly in lower resource areas; Additionally, production scaling from lab to industry while maintaining consistency and reproducibility of product in an ongoing basis remains a challenge (Ventola, 2017).

Nanoparticle-based medicines face many significant regulatory hurdles from a regulatory body. This is primarily due to the fact that there are no global standards currently available. The current regulations for normal medications do not apply properly to nanomaterials, due to their different physicochemical and biological properties. This results in differing evaluation criteria from country to country, thus complicating the approval process and global utilization. (Fadeel et al., 2018).

Another major regulatory concern is determining safety and efficacy. Traditional toxicology study procedures may not be appropriate for nanoparticles, as their properties are very different from the bulk material. Quality characterization, long-term toxicology studies, and standard operating procedures for performing all studies are still being developed. These unknowns create difficulty for risk assessment and making regulatory decisions (Rauscher et al., 2017).

There exists a critical gap in the clinical implementation of new technologies due to the translational gap which is caused by the difference between the research/researcher and the using/implementing healthcare provider. There have been many different formulations (of nanoparticles) which have passed through and shown promise in preclinical studies; however, very few of them have moved on to be clinically available. This large translational gap is primarily attributed to not performing sufficient clinical validation on a large scale, problems associated with reproducibility, and complex regulatory obstacles associated with the approval process. To bridge this gap there needs to be increased clinical trials with an appropriate standardized framework for evaluation. (Anselmo & Mitragotri, 2016).

Economic and scalability issues further restrict industrial adoption. The transition from experimental formulations to commercially viable products demands cost-effective manufacturing, regulatory approval, and market acceptance. These factors collectively influence the feasibility of nanoparticle-based therapeutics in real-world healthcare systems. (Ventola, 2017).

While the challenges of nanoparticle systems are many, their future potential remains bright as a result of continuous advancements in nanotechnology. Nanotechnology will contribute to many of the new developments in smart nanoparticles that are responsive to environmental stimuli, such as pH, temperature, or enzyme activity for controlled release of drugs with excellent precision and accuracy (Torchilin, 2014).

The combination of nanoparticles mixed with artificial intelligence and precision diagnostics has the potential to create an entirely new way of designing and optimizing therapeutic modalities. By utilizing AI-driven models to predict nanoparticle behaviour, optimize formulations, and personalize therapy, this convergence of nanotechnology and AI will create an environment to further enhance innovation in targeted therapeutics.

In addition, it is anticipated that nanoparticles will play a significant role in personalizing therapies for individual patients. Nanoparticle systems offer unique advantages in the targeted and effective delivery of medications through the tailoring of therapies based on patient-specific characteristics and disease profiles and therefore, are expected to support the evolution of next-generation therapeutic modalities.

Finally, achieving successful outcomes with nanoparticle-based therapeutics requires collaboration among scientists, clinicians, engineers, and policy-makers from multiple

disciplines. To overcome existing obstacles and facilitate the safe and effective application of these technologies, it will be critical to provide policy interventions, establish standardized regulatory mechanisms, and make increased investments into research and development.

5. CONCLUSION AND RECOMMENDATIONS

Conclusion

Research has indicated that the continuing rise of nanoparticles as a platform to change the way we treat patients with cancer and other chronic diseases is occurring rapidly. The advanced methods of delivering drugs using NP have also demonstrated advances in both precision of therapy and how quickly drugs can be delivered to patients. In particular, NP such as liposomes, dendrimers, and metallic carriers have been shown to have the ability to deliver medications to specific areas of the body that need treatment. By using these types of carriers, the therapeutic results of the medications being delivered can be improved by reducing any adverse effects from a medication on healthy tissue. This is particularly helpful for patients receiving chemotherapy because NP which will deliver chemotherapy to the site of disease and not have as drastic systemic effects as traditional (non-targeted) chemotherapy has.

The study also emphasized that NP delivery systems provide higher rates of drug bio-availability to patients as well as extended half-lives of the medications once administered. Both of these factors are important for long-term management of chronic diseases. For patients who have chronic disorders such as diabetes, cardiovascular disease or neurodegenerative disease, using NP delivery methods for medications may also assist patients in maintaining adherence to their prescribed medication regimen and reducing the frequency of dosing. The added benefit of NP being able to cross biological barriers and sustain the release of drugs once inside the body has helped to solidify their place within today's new pharmaceutical sciences.

Nonetheless, despite these encouraging advances, the research identified a number of difficulties that have hindered the broad clinical acceptance of nanoparticles as therapeutic agents. Concerns have been raised about biocompatibility, long-term toxicity and stability with regard to the safety of patients. The complexity and high costs associated with production processes have also limited the ability to produce large quantities and deliver them effectively to patients. Furthermore, regulatory uncertainties and the lack of globally harmonized standards have delayed the approval and commercialization of many nanoparticle-based

products. These challenges indicate that although there have been substantial advances in nanoparticle-based therapies, they have not yet achieved their full clinical potential.

Recommendations

When it comes to overcoming these challenges and promoting nanoparticle-based drug delivery systems, there are several critical recommendations to consider. The first involves the strengthening of regulatory frameworks by creating standard, comprehensive and globally accepted guidelines for the evaluation and approval of nanoparticle therapeutics. These frameworks should include the unique properties of nanoparticle-based drugs and ensure uniform assessments for safety and effectiveness.

The second recommendation suggests that future research must be more focused on understanding the long-term safety, toxicity and biocompatibility of nanoparticles. Comprehensive research must be undertaken to investigate the interaction of nanoparticles with biological systems over long periods of time as this will help establish confidence with regulatory bodies and healthcare professionals.

The third recommendation states that resources should be directed toward developing cost-effective and scalable manufacturing techniques. The simplification of processes and improving reproducibility is vital for increasing accessibility and commercial viability in the use of nanoparticle-based therapeutics, particularly in resource-poor areas.

Lastly, improved collaboration among researchers, clinicians, pharmaceutical manufacturers and policymakers is essential. Interdisciplinary collaboration will allow for quick and efficient application of research and innovations to meet the needs of the healthcare system.

In conclusion, there is a need for developing evidence-based guidelines for integrating nanoparticle-based systems into standard clinical practice. In order for these advanced therapeutic systems to be safe and effective, they must undergo clinical validation. Standardized protocols and practitioner awareness of how to use these types of systems effectively will help ensure their safety and effectiveness. Addressing these strategic areas will allow for better use of nanoparticle platforms to change the way targeted therapies are delivered and to improve outcomes for patients with chronic diseases as well as those with cancers.

References

1. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews, 65*(1), 36–48. https://www.sciencedirect.com/science/article/pii/S0169409X12001794

2. Anselmo, A. C., & Mitragotri, S. (2016). Nanoparticles in the clinic. *Bioengineering & Translational Medicine, 1*(1), 10–29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398808/

3. Anselmo, A. C., & Mitragotri, S. (2019). Nanoparticles in the clinic: An update. *Bioengineering & Translational Medicine, 4*(3), e10143. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769746/

4. Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016). Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. *Pharmaceutical Research, 33*(10), 2373–2387. https://link.springer.com/article/10.1007/s11095-016-1958-5

5. Buzea, C., Pacheco, I. I., & Robbie, K. (2007). Nanomaterials and nanoparticles: Sources and toxicity. *Biointerphases, 2*(4), MR17–MR71. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924870/

6. Cullis, P. R., & Hope, M. J. (2017). Lipid nanoparticle systems for enabling gene therapies. *Molecular Therapy, 25*(7), 1467–1475. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498813/

7. Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. *Journal of Controlled Release, 148*(2), 135–146. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957257/

8. DiSanto, R. M., Subramanian, V., & Gu, Z. (2015). Recent advances in nanotechnology for diabetes treatment. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 7*(4), 548–564. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478103/

9. Dykman, L. A., & Khlebtsov, N. G. (2012). Gold nanoparticles in biomedical applications: Recent advances and perspectives. *Chemical Society Reviews, 41*(6), 2256–2282. https://pubs.rsc.org/en/content/articlelanding/2012/cs/c1cs15166e

10. Fadeel, B., Farcal, L., Hardy, B., Vázquez-Campos, S., Hristozov, D., Marcomini, A., Lynch, I., Valsami-Jones, E., Alenius, H., Savolainen, K., & others. (2018). Advanced tools for the safety assessment of nanomaterials. *Nature Nanotechnology, 13*(7), 537–543. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061012/

11. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. *ACS Nano, 3*(1), 16–20. https://pubs.acs.org/doi/10.1021/nn900002m

12. Kesharwani, P., Jain, K., & Jain, N. K. (2014). Dendrimer as nanocarrier for drug delivery. *Progress in Polymer Science, 39*(2), 268–307. https://www.sciencedirect.com/science/article/pii/S0079670013000600

13. Maeda, H., Nakamura, H., & Fang, J. (2013). The EPR effect for macromolecular drug delivery to solid tumors. *Advanced Drug Delivery Reviews, 65*(1), 71–79. https://www.sciencedirect.com/science/article/pii/S0169409X12000523

14. Mukherjee, S., Ray, S., & Thakur, R. S. (2009). Solid lipid nanoparticles: A modern formulation approach in drug delivery system. *Indian Journal of Pharmaceutical Sciences, 71*(4), 349–358. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840782/

15. Omidian, H., Babanejad, N., & Cubeddu, L. X. (2023). Nanosystems in cardiovascular medicine: Advancements, applications, and future perspectives. *Pharmaceutics, 15*(7), 1935. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386572/

16. Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. *Nature Reviews Drug Discovery, 17*(4), 261–279. https://www.nature.com/articles/nrd.2017.243

17. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., & Shin, H. S. (2018). Nano based drug delivery systems: Recent developments and future prospects. *Journal of Nanobiotechnology, 16*(1), 71. https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-018-0392-8

18. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotechnology, 2*(12), 751–760. https://www.nature.com/articles/nnano.2007.387

19. Rauscher, H., Roebben, G., Mech, A., Gibson, N., Kestens, V., Linsinger, T. P. J., Riego Sintes, J., & Rasmussen, K. (2017). An overview of concepts and terms used in the European Commission's definition of nanomaterial. *Joint Research Centre Report*. https://publications.jrc.ec.europa.eu/repository/handle/JRC113469

20. Rodríguez, F., Caruana, P., De la Fuente, N., Español, P., Gámez, M., Balart, J., Llurba, E., Rovira, R., Martin-Lluesma, S., Viñas, G., Corchero, J. L., & Céspedes, M. V. (2022). Nano-based approved pharmaceuticals for cancer treatment: Present and future challenges. *Biomolecules, 12*(6), 784. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221343/

21. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. *Frontiers in Pharmacology, 6*, 286. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676809/

22. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. *Frontiers in Pharmacology, 6*, 286. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676809/

23. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. *Nature Reviews Cancer, 17*(1), 20–37. https://www.nature.com/articles/nrc.2016.108

24. Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nature Reviews Drug Discovery, 13*(11), 813–827. https://www.nature.com/articles/nrd4333

25. Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nature Reviews Drug Discovery, 13*(11), 813–827. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213084/

26. Ventola, C. L. (2017). Progress in nanomedicine: Approved and investigational nanodrugs. *Pharmacy and Therapeutics, 42*(12), 742–755. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725809/

27. Ventola, C. L. (2017). Progress in nanomedicine: Approved and investigational nanodrugs. *Pharmacy and Therapeutics, 42*(12), 742–755. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724087/

28. Wechsler, M. E., Vela Ramirez, J. E., & Peppas, N. A. (2019). Nanoparticle mediated drug delivery for the treatment of Alzheimer's disease: Crossing the blood–brain barrier. *Industrial & Engineering Chemistry Research, 58*(33), 15079–15087. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518412/

29. World Health Organization. (2023). Cancer fact sheet. https://www.who.int/news-room/fact-sheets/detail/cancer